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as a ﬁrst-line agent against intravenous vancomycin in treating
methicillin-resistant Staphylococcus aureus–conﬁrmed nosocomial
pneumonia in four Chinese cities. Methods: A decision-analytic
model of 4-week time horizon was used to conduct cost-
effectiveness analyses from the payer’s perspective. Clinical outcomes
and resource use data were derived from a head-to-head trial, supp-
lemented with local cost estimates based on hospital data via an
expert panel. A series of scenario analyses were conducted to evaluate
the impact of uncertainty around model inputs. All results were
reported in 2012 Chinese Renminbi. Results: The predicted probability
of overall treatment success was 0.629 and 0.602 for linezolid and
vancomycin, respectively. Total inpatient costs varied across the four
cities, ranging from ¥58,835 to ¥86,894 for linezolid and ¥58,390 to
¥87,033 for vancomycin, respectively. Linezolid was demonstrated to
be a dominant treatment strategy in Guangzhou. In Beijing, Nanjing,ee front matter Copyright & 2014, International S
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pore 048424.and Xi’an, incremental cost-effectiveness ratios in terms of additional
successfully treated patient were ¥1,861, ¥163, and ¥16,509, respec-
tively. Dominance by linezolid was observed in some scenario anal-
yses with parameters such as treatment duration, inclusion of cost of
managing adverse events, and drug acquisition costs being the main
drivers of cost-effectiveness results. Conclusions: Despite linezolid’s
higher drug acquisition cost, its superior clinical efﬁcacy renders it a
likely cost-effective alternative for the treatment of methicillin-
resistant Staphylococcus aureus–conﬁrmed nosocomial pneumonia as
compared with branded vancomycin from the payer perspectives of
Beijing, Guangzhou, Nanjing, and Xi’an.
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Nosocomial pneumonia (NP) caused by Staphylococcus aureus is
the most commonly observed infection within the hospital
setting in the United States, Europe, and Asia including China
[1], with increasing evidence of resistance to methicillin [2,3]. In a
review based on published clinical studies conducted in Europe,
the prevalence of methicillin-resistant Staphylococcus aureus
(MRSA) in clinical settings could be as high as approximately
one-third of all clinical isolates of S aureus [4]. In another study
with a special focus on ventilator-associated pneumonia, a rate
of up to 80% was reported [5]. In China, a study concluded a meanMRSA prevalence of 50.4%, with the highest in Shanghai (80.3%),
followed by Beijing (55.5%) and Shenyang (50.0%) [6]. MRSA
infections are associated with considerable attributable mortality
and morbidity resulting in high health care burden [7,8].
Vancomycin has always been a standard treatment for MRSA
infection [9]. The presence of vancomycin-intermediate S aureus,
however, has become increasingly more common [10,11]. Con-
cerns over its nephrotoxicity, inadequate penetration into lungs,
and the need for intravenous (IV) administration may limit
its use.
Linezolid is an oxazolidinone antibiotic and has a unique
mechanism of action that inhibits bacterial protein synthesis atociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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action, cross-resistance with other antimicrobials does not
develop easily [12]. In addition, the oral bioavailability of linezolid
is almost 100% [13], thus allowing IV to oral therapy switch
without changing the antibacterial agent or dosage regimen.
Compared with vancomycin, linezolid is relatively new and
has been approved in China for the treatment of skin and soft
tissue infections and hospital-acquired and community-acquired
pneumonia. Superior efﬁcacy of linezolid compared with vanco-
mycin was demonstrated in a recently published head-to-head
MRSA NP clinical study by Wunderink et al. [14].
Previous cost-effectiveness studies showed that linezolid was
cost-effective compared with vancomycin in treating NP across
different country settings, such as Brazil [15], Germany [16], Spain
[17], and the United States [18,19]. To our knowledge and through
a review of literature, there has not been any published cost-
effectiveness study comparing linezolid against vancomycin in a
Chinese setting. This study attempted to ﬁll this gap by evaluat-
ing the cost-effectiveness of linezolid against vancomycin in
treating MRSA conﬁrmed NP from a payer’s perspective across
four geographically representative Chinese cities—Beijing, Nanj-
ing, Guangzhou, and Xi’an—given that there exist wide variations
in affordability as measured by gross domestic product per capita
and in health care cost across different regions in China. Despite
the fact that cost-effectiveness analysis is not currently formally
required in the evaluation process for national reimbursement
drug listing, a single cost-effectiveness threshold may not be
applicable in the context of China.Methods
Overall Model Description
A decision-analytic model was developed to estimate relevant
costs and health outcomes of linezolid or vancomycin for
hospitalized patients with MRSA-conﬁrmed NP. Clinical and
resource use parameters used in this study were identiﬁed from
the Wunderink et al. [14] trial and its subsequent post hoc
published analysis [20], while the local resource use and cost
data were provided through review of local published literature
and surveys with local clinicians who were experienced in
managing MRSA conﬁrmed NP. The incremental cost-
effectiveness ratio (ICER) in terms of additional successfully
treated patient was performed in the context of each cityFig. 1 – A decision-analytic model structure. AEs, adverse even
nosocomial pneumonia.included in this study.Cost-Effectiveness Model Structure
The model starts with a hypothetical patient for suspected or
conﬁrmed gram positive NP (Fig. 1). The empirical treatment with
IV vancomycin or linezolid was considered for a period of 2 days
before culture results were available. On MRSA conﬁrmation with
laboratory results, the patient was placed on ﬁrst-line treatment
with linezolid or vancomycin for up to a maximum of 14 days.
Possible outcomes of ﬁrst-line treatment were: 1) treatment
success (resolution of symptoms or clinical improvement);
2) treatment failure due to lack of efﬁcacy; 3) discontinuation
due to adverse events (AEs); and 4) death. In case of treatment
failure or discontinuation caused by AEs, the patient was
switched to second-line treatment on day 7 of the ﬁrst-line
treatment. The same maximum therapy duration of 14 days
was assumed for second-line treatment. The model also included
an additional hospital stay of 1.7 and 2 days in the event of
adverse event or treatment failure, respectively, based on the
post hoc data analysis of Wunderink et al. trial [20] and inputs
from local clinical experts. Because of lack of relevant published
data, clinical inputs for second-line treatment were assumed to
be the same as those of the ﬁrst-line treatment, which were
primarily obtained from the Wunderink et al. [14] trial. Consistent
with previously published NP economic models [19,21], third-line
treatment was not considered in this study because it was
believed that most of the relevant costs and outcomes would be
captured in the ﬁrst and second lines of treatments. In accord-
ance with the feedback from local clinical experts, patients who
failed ﬁrst-line linezolid were assumed to switch to second-line
vancomycin and vice versa. Therefore, in the absence of post-
hospitalization data, a time horizon of 4 weeks of an episode of
NP caused by MRSA was adopted in line with the standard
clinical practice mentioned above. In a separate study by De
Cock et al. [16], the same clinical consideration was applied with
similar hospital lengths of stay of 28.1 days being reported for
both study and comparator groups treated with linezolid and
vancomycin, respectively. In addition, a local retrospective data-
base analysis reported an average length of hospital stay of 23.8
days among 610 patients treated for NP in 13 tier-3A hospitals in
China [22]. Furthermore, it is unlikely that there will be signiﬁcant
differences in terms of cost and effectiveness between two study
groups upon recovery and discharge from hospitals.ts; MRSA, methicillin resistance staphylococcus aureus; NP,
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ness over the time horizon of 4 weeks for linezolid and vanco-
mycin. Effectiveness was deﬁned as the probability of a patient
being successfully treated, which was based on the treatment
cure rates from a published trial [14]. The cost-effectiveness
results in this study were presented as the incremental cost in
terms of additional successfully treated patient for comparison
between linezolid and vancomycin. In the case of linezolid,
treatment results in, on average, a greater number of additional
successfully treated patients at a lower overall estimated total
inpatient cost and linezolid is considered dominant over vanco-
mycin.
ICER ¼ Costlinezolid2Costvancomycin
Effectivenesslinezolid2EffectivenessvancomycinClinical Expert Panel
Given that most of the MRSA-conﬁrmed NP cases in China are
treated in tier-3A hospitals in which facilities such as intensive
care units (ICUs) are available, a total of 25 clinical experts with
experience in managing NP at major tier-3A hospitals in these
four representative cities (Beijing, Guangzhou, Nanjing, and
Xi’an) within the study scope were recruited and surveyed
through a series of structured interviews. This physician sample
represented four to six main tier-3A representative hospitals in
each of these cities within the study scope. Recognizing the
limitation of not including all the tier-3A hospitals in these cities
in our sample, the effect of uncertainty surrounding the resource
use and cost data inputs obtained through surveys in our study
was assessed through a series of scenario analyses. Besides, in
general, all the clinical experts agreed with the model structure,
assumptions, and key data inputs given the similarity in local
and overseas clinical practice in managing MRSA-conﬁrmed NPTable 1 – Input values for base-case analysis.
Parameters Linezo
(Zyvo
Efﬁcacy rates, % 54.8
Mortality rates, % 27.2
Rates of adverse events leading to treatment
discontinuation, %
1.78
Rates of treatment failure leading to treatment
discontinuation, %
15.3
No. of days of treatment (both ﬁrst and second
treatments)
10
Total lengths of hospital stay 17.9
No. of ICU stays (d) 10.1
No. of general ward stays (d) 7.8
Days of ﬁrst-line drug use before switching to a second-
line drug
7
Drug acquisition unit costs (¥) 453 per
Average daily costs (¥)
General ward
Beijing 860
Guangzhou 910
Nanjing 880
Xi’an 692
Intensive care unit (ICU)
Beijing 6500
Guangzhou 7500
Nanjing 6700
Xi’an 4750cases as reﬂected in the model. The main antibiotic options in
Chinese hospitals for treating MRSA conﬁrmed NP are vancomy-
cin and linezolid. In China, however, it is not a common clinical
practice to switch patients receiving IV linezolid to oral linezolid
even though their condition may allow for the switch. Therefore,
this scenario was not included in the analysis. The clinicians also
highlighted that given the quality concerns over the use of
generic products, branded vancomycin would always be used,
especially in critical clinical conditions such as NP. Hence,
Vancocin CP was considered as the comparator to linezolid
(Zyvox) for the cost-effectiveness analyses in this study. The
model inputs for the remaining parameters such as efﬁcacy and
AEs were based on analyses reported in the Wunderink et al. [14]
trial and its subsequent post hoc published analysis [20].Input parameters
Taking a relatively conservative approach, clinical success rates
in the modiﬁed intention-to-treat patients at end of study
reported in the Wunderink et al. [14] trial were used as estimates
for the treatment success outcomes of linezolid and vancomycin
in the model. In the Wunderink et al. trial, clinical success/cure
was deﬁned as resolution of clinical signs and symptoms of
pneumonia; compared with baseline, improvement or lack of
progression in chest imaging; and no requirement for additional
antibacterial treatment. To prevent double counting, an overall
mortality rate was considered over 4 weeks covering both the
ﬁrst- and second-line treatments using modiﬁed intention-to-
treat population-based weighted average 60-day mortality data
reported in the Wunderink et al. [14] trial. Because most of the
deaths happened during the ﬁrst 30 days, the effect of using 60-
day mortality data in this study was therefore assumed to be
negligible compared with using 30-day data. In addition, given a
lack of signiﬁcant difference in 60-day mortality results between
linezolid and vancomycin treatment groups in the Wunderinklid
x)
Vancomycin (Vancocin
CP)
References
44.9 [14]
27.2 [14]
3.13 [14]
2 25.68 [14]
10 [20]
18.6 [20]
10.6
8.0
7 Expert panel
vial 144 per vial Hospital data
Hospital ICU ﬁnancial
reports860
910
880
692
6500
7500
6700
4750
Table 2 – Results from cost-effectiveness analysis—
base case.
Beijing Lin Van
Inpatient drug costs (¥) 9,608 7,806
Inpatient medical costs (¥) 67,152 68,903
Total inpatient cost (¥) 76,759 76,709
Proportion of successfully treated patients 0.629 0.602
Lin vs. Van
Incremental total inpatient cost (¥) 50
Incremental effectiveness 0.027
ICER in terms of additional successfully treated
patient (¥)
1,861
Guangzhou Lin Van
Inpatient drug costs (¥) 9,608 7,806
Inpatient medical costs (¥) 77,286 79,227
Total inpatient costs (¥) 86,894 87,033
Proportion of successfully treated patients 0.629 0.602
Lin vs. Van
Incremental total inpatient cost (¥) −139
Incremental effectiveness 0.027
ICER in terms of additional successfully treated
patient
Dominated by Lin
Nanjing Lin Van
Inpatient drug costs (¥) 9,608 7,806
Inpatient medical costs (¥) 69,202 70,999
Total inpatient costs (¥) 78,809 78,805
Proportion of successfully treated patients 0.629 0.602
Lin vs. Van
Incremental total inpatient cost (¥) 4
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treatments. The study discontinuation rates due to severe AEs
reported in the same trial were used to provide the probability of
AEs leading to therapy switch in the model. Last, the probability
of treatment failure among survivors was calculated as 1 –
(probability of success þ probability of AEs þ probability of
mortality).
Inputs from clinical experts were used to validate the resource
utilization data (length of general ward and ICU stay) obtained
from the post hoc analysis of the Wunderink et al. trial data [20].
The number of antibiotic treatment days ranges from 10 to 14
days for both linezolid and vancomycin. In general, for a clinical
case similar to those patients investigated in the Wunderink et al.
[14] trial, the expert panel suggested a range of 7 to 14 days of ICU
stay followed by another week in the general ward. These
estimates were close to the ﬁndings of 10.1 and 7.8 days,
respectively, for linezolid and 10.6 and 8 days, respectively, for
vancomycin reported from the post hoc analysis of Wunderink
et al. trial data [20].
Daily costs were averaged by city for hospital stay in a
general ward and an ICU. These values were based on estimates
provided by local clinical experts in reference to currently
available annual or quarterly ﬁnancial and admission ﬁgures
of patients treated in ICUs of these hospitals. The total inpatient
costs included drug acquisition, clinical consultations, nursing
care, hospital bed, mechanical ventilation, IV administration
and laboratory testing, and other ancillary costs, if any. Con-
sistent drug acquisition costs were reported for a vial of 600 mg
Zyvox and a vial of 500 mg Vancocin CP across four different
cities. The input values for base-case analysis are given in
Table 1.
Scenario Analysis
The robustness of the cost-effectiveness results was further
assessed by conducting a series of scenario analyses on param-
eters such as treatment duration, day of drug switch, inclusion of
speciﬁc AEs, daily ICU cost, daily general ward cost, and drug and
AE costs. On the basis of adverse rates observed in the Wunder-
ink et al. [14] trial and the post hoc analysis [20], we estimated
and included the costs of managing common AEs such as renal
failure (linezolid: 4.02% vs. vancomycin: 15.18%) and thrombocy-
topenia (linezolid: 16.3% vs. vancomycin: 13.2%) in the scenario
analyses. Published average additional stay of 3.2 days in the ICU
and 0.6 days in the general ward for renal failure [20] and an
additional stay of 2.7 days in the general ward for drug-induced
thrombocytopenia [23] were applied together with the average
daily costs in the ICU and the general ward for different cities in
the AE cost estimation.
A total of eight scenario analyses were evaluated in our
analysis (Table 3).Incremental effectiveness 0.027
ICER in terms of additional successfully treated
patient (¥)
163
Xi’an Lin Van
Inpatient drug costs (¥) 9,608 7,806
Inpatient medical costs (¥) 49,227 50,585
Total inpatient costs (¥) 58,835 58,390
Proportion of successfully treated patients 0.629 0.602
Lin vs. Van
Incremental total inpatient cost (¥) 445
Incremental effectiveness 0.027
ICER in terms of additional successfully treated
patient (¥)
16,509
ICER, incremental cost-effectiveness ratio; Lin, linezolid; Van,
vancomycin.Results
Cost-Effectiveness Analysis
Considering both ﬁrst- and second-line treatment strategies, the
model estimated treatment success probability to be 0.629 and
0.602 for linezolid and vancomycin, respectively. Because of
different daily costs for hospital stay in the general ward and
the ICU, the estimated overall total inpatient costs for treatment
starting with linezolid and vancomycin varied across the four
cities. Based on the total hospital stay of 17.9 days and 18.6 days
as reported for linezolid and vancomycin, respectively [20],
overall total inpatient costs ranging from ¥58, 390 in Xi’an to
¥87, 033 (Table 2) in Guangzhou were estimated by the adaptedmodel. Linezolid was estimated to have greater effectiveness in
successfully treating patients (by 0.027 or 2.7%) and lower total
inpatient costs (by ¥139) resulting in a “dominant” treatment
option (with a higher probability of treatment success and a
lower total treatment cost) compared with vancomycin for the
Guangzhou region scenario. In contrast, for Beijing, Nanjing, and
Xi’an, the ICERs in terms of additional successfully treated
patient were estimated at ¥1,861, ¥163, and ¥16,509, respectively
(Table 2).
Scenario Analysis
Based on the expert panel’s opinions, a series of scenario
analyses were conducted by varying the values of resource
utilization and unit costs. The ICERs in terms of additional
successfully treated patient for each scenario are given in
Table 3 for the context of four different cities. Dominance of
linezolid over vancomycin was observed in most of the scenario
analyses for Beijing, Guangzhou, and Nanjing. The total inpatient
Table 3 – Results from scenario analysis—by city.
Parameters and values ICER in terms of additional successfully treated patient (¥)
BJ GZ NJ XN
Base case 1,861 Dominated by Lin 163 16,509
I. Treatment duration (d)
7 Dominated by Lin Dominated by Lin Dominated by Lin Dominated by Lin
14 Dominated by Lin Dominated by Lin Dominated by Lin 14,219
II. Day of drug switch
3 14,718 8,435 13,314 26,895
9 Dominated by Lin Dominated by Lin Dominated by Lin 12,751
III. Inclusion of AEs
Speciﬁc AEs: renal failure* and thrombocytopenia† Dominated by Lin Dominated by Lin Dominated by Lin Dominated by Lin
þ20%‡ in AE costs Dominated by Lin Dominated by Lin Dominated by Lin Dominated by Lin
IV. Daily ICU cost
−20%‡ 9,074 3,165 7,598 21,780
þ20%‡ Dominated by Lin Dominated by Lin Dominated by Lin 11,238
V. Daily GW cost
−20%‡ 6,917 193 5,337 20,578
þ20%‡ Dominated by Lin Dominated by Lin Dominated by Lin 12,440
VI. Drug cost: Linezolid (Zyvox)
−20%‡ Dominated by Lin Dominated by Lin Dominated by Lin Dominated by Lin
−10%‡ Dominated by Lin Dominated by Lin Dominated by Lin Dominated by Lin
VII. Drug cost: Vancomycin (Vancocin CP)
−20%‡ 33,360 26,342 31,663 48,009
−10%‡ 17,611 10,593 15,913 32,259
VIII. Drug costs: Linezolid (Zyvox) and Vancomycin (Vancocin CP)
−20%‡ Dominated by Lin Dominated by Lin Dominated by Lin 3,126
−13%‡ Dominated by Lin Dominated by Lin Dominated by Lin 7,810
AEs, adverse events; BJ, Beijing; ER, emergency room; GW, general ward; GZ, Guangzhou; ICER, incremental cost-effectiveness ratio; ICU,
intensive care unit; Lin, linezolid; NJ, Nanjing; XN, Xi’an.
* Estimated total in-patient costs due to drug-induced renal failure: ¥21,316 (BJ), ¥24,546 (GZ), ¥21,968 (NJ), and ¥15,615 (XN).
† Estimated total in-patient costs due to drug-induced thrombocytopenia: ¥2,322 (BJ), ¥2,457 (GZ), ¥2,376 (NJ), and ¥1,868 (XN).
‡ Increase or reduction in the corresponding cost from those considered in the base-case analysis.
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resulting in a higher ICER when the switch to second line due
to ﬁrst-line failure or AEs was accelerated from day 7 to day 3. As
expected, the ICERs (for using linezolid over vancomycin)
increased as the per day total costs in the general ward and the
ICU reduced, providing less cost offset attributed to shorter
hospital stay as reported for treatment with linezolid. The same
was observed in ICERs in the scenarios of lower drug acquisition
cost of Vancocin CP, resulting in higher incremental total inpa-
tient costs for using linezolid over vancomycin. Xi’an regional
analysis observed a similar trend because of lower hospital stay
unit costs that were reported for tier-3A hospitals as compared
with those in other cities.
An additional scenario of removal of hospital margin of 13%
on drug costs as part of the national health care reform by the
National Development and Reform Commission of People’s
Republic of China [24] was tested for the drug acquisition cost
of a vial of 600 mg Zyvox and a vial of 500 mg Vancocin CP at ¥400
and ¥125, respectively. Dominance by linezolid over vancomycin
was observed in this scenario for Beijing, Guangzhou, and Nanj-
ing except Xi’an with an ICER of ¥7, 810 for each additional
successfully treated patient.Discussion
NP caused by MRSA places a substantial economic burden on the
hospital through the use of health care resources. Although
linezolid had a higher drug acquisition cost, it provided greaterefﬁcacy and resulted in lower inpatient medical costs due to less
resource use, for example, shorter ICU and general ward stays
and therefore a total inpatient cost saving against vancomycin.
Because of differences in cost per day of hospitalization (general
ward and ICU) across the four cities, the estimated total inpatient
costs for treatment with linezolid and vancomycin varied among
these cities. Costs of ICU and general ward stay in Xi’an were
found to be lower than those reported for other cities. The overall
total inpatient costs (¥58,390–¥87,033), estimated by the adapted
model for these cities for hospital stays of 17.9 days and 18.6
days, are likely to be conservative in comparison to the reported
average total inpatient cost of ¥108,950 over an average hospital
stay of 23.8 days published in a retrospective database analysis of
597 hospital-acquired pneumonia cases across 13 tier-3A hospi-
tals in nine cities in China [22]. This reported ﬁgure, however,
also included data of all other hospital-acquired pneumonia
cases, not limited to only MRSA conﬁrmed NP cases.
As the Wunderink et al. [14] trial showed that linezolid
presented higher efﬁcacy resulting in lower health resource
utilization, linezolid was more efﬁcacious in patients with MRSA
conﬁrmed NP, offering an advantage in terms of both clinical cure
rate and AE rate such as renal toxicity [25,26]. Using the superior
efﬁcacy data reported from the head-to-head Wunderink et al.
[14] trial, resource utilization data from the post hoc analysis [20],
and local unit costs, our base-case results of dominance by
linezolid and relatively low ICERs of less than ¥20,000 in terms
of additional successfully treated patient suggest that linezolid is
likely to be a cost-effective option compared with branded
vancomycin in the contexts of four cities in China. The 2012
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cities are in the region of ¥51,000 for Xi’an to ¥106,000 for
Guangzhou [27]. The cost-effectiveness results of linezolid were
further conﬁrmed by the resulting ICERs in a series of scenario
analyses that evaluated the uncertainty in resource use and cost
inputs. Dominance by linezolid was also observed for Beijing,
Guangzhou, and Nanjing in a likely scenario of removing 13%
margin on drug costs by the hospitals as part of the health care
reform by the National Development and Reform Commission of
People’s Republic of China. In the same scenario, the ICER
reduced from ¥16,509 to ¥7,810 for Xi’an. In a separate scenario
analysis of inclusion of costs in managing AEs such as renal
failure and thrombocytopenia using the resource use data
reported in post hoc analysis of the Wunderink et al. [20] trial,
dominance over vancomycin by linezolid was demonstrated
across all four cities. In summary, as shown in the results of
scenario analyses (Table 3), parameters such as treatment dura-
tion, inclusion of cost of managing AEs, and drug acquisition
costs are the main drivers presenting the most uncertainty to the
cost-effectiveness results.
We believe that the resulting ICERs, for both base-case and
scenario analyses, in this study are conservative. For example,
based on the expert opinions, laboratory facility of measuring
serum vancomycin is not common among the tier-3A hospitals in
China; therefore, without proper monitoring and adjustment of
vancomycin dosing regimen in these critically ill patients, the
renal toxicity rates based on the Wunderink et al. trial are likely
to be conservative for the local contexts in China. This means for
additional costs to manage higher rates of vancomycin-induced
toxicities, the ICERs would be lower than what have been
estimated in this study, further conﬁrming that linezolid is more
cost-effective than branded vancomycin in treating patients with
MRSA conﬁrmed NP in China. On a separate but relevant note,
reduction in total per-patient hospital costs has been shown to be
associated with the use of linezolid in a number of published
studies [28,29].
Furthermore, in the absence of published efﬁcacy data of
linezolid and vancomycin as a second-line treatment, it is a
conservative approach to assume and apply the same efﬁcacy
reported in the Wunderink et al. trial [14] in which both these
drugs were compared and investigated as a ﬁrst-line treatment.
We believe that the efﬁcacy of these drugs as a second-line
treatment might be lower, particularly for those who failed either
linezolid or vancomycin as their ﬁrst-line treatment. Pertinent to
this discussion, a recent study by Mullins et al. [30] concluded
that the likelihood of a rehospitalization among adult patients
treated for infection was lower in both absolute and relative
terms for those treated with linezolid versus vancomycin. In
addition, the beneﬁt of switching from IV to oral formulation
resulting in a shorter duration IV therapy and hence lower
administration costs and earlier hospital discharge was not taken
into account in our analysis. Such beneﬁt has been demonstrated
in the cost-effectiveness studies carried out in various countries
[21,29,31,32]. Also, the potential work productivity gain through
early discharge from a shorter hospital stay for patients treated
with linezolid was not captured in our model. In view of all the
above considerations, the ICERs reported in this study may have
been overestimated.
Several limitations should be taken note of while interpreting
our ﬁndings. First, local cost data that are derived from appro-
priately sampled patient-level data of each hospital would be
ideal as the model inputs. This still remains a challenge, how-
ever, to conduct health service research in most of the developing
countries including China. Therefore, we aimed to address this
limitation by conducting a series of scenario analyses to evaluate
the effect of uncertainty around the local cost inputs on the cost-
effectiveness results of this study. Second, cost-effectivenessresults would tend to be interpreted in terms of incremental cost
per quality-adjusted life-year against a recommended threshold
such as one to three times the gross domestic product per capita
by the World Health Organization [33]. Further research is
suggested to include the quality-of-life data to allow analysis in
incremental cost per quality-adjusted life-year gained. Another
limitation of our model is the short time horizon of 4 weeks in
which lifetime resource use and beneﬁts, if any, might have been
missed in the current analysis. Therefore, it is recommended to
consider all the above in the future cost-effectiveness analysis of
linezolid in treating MRSA conﬁrmed NP. It is worth, however,
highlighting that given patients with NP are generally older,
suffering from numerous comorbidities that may complicate
treatment, and have factors that put them at a higher risk of
acquiring mixed infection, the ﬁndings in a cost-effectiveness
study in MRSA conﬁrmed NP may not be generalized across
different health care settings and need to be interpreted with
caution.
To our knowledge, this study is the ﬁrst cost-effectiveness
analysis for MRSA conﬁrmed NP in a Chinese setting using the
recent head-to-head linezolid versus vancomycin trial data
reported in Wunderink et al. [14]. Thus, it would be interesting
to investigate and compare the results of previous cost-
effectiveness analyses against those using the same models but
based on the data reported in the Wunderink et al. [14] trial.Conclusions
Despite a higher direct drug acquisition cost of linezolid in China,
our analyses suggest that, given its superior efﬁcacy and out-
comes, linezolid is likely a cost-effective alternative for the ﬁrst-
line treatment of MRSA conﬁrmed NP as compared with branded
vancomycin from the local payer perspectives of Beijing, Guangz-
hou, Nanjing, and Xi’an.
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